Loading
Chronic Obstructive Pulmonary Disease (COPD) Research / Lung Cancer Diagnosis and Treatment · Journal article
Scientific Reports · August 18, 2026
Reinforces what was already believed, rather than introducing something new.
In a multicenter retrospective cohort of 455 patients with spirometry-confirmed COPD and advanced/recurrent NSCLC, regular inhaled COPD therapy was associated with longer median overall survival (23.3 vs 16.7 months; HR 0.73, 95% CI 0.57–0.93; p=0.0105). However, this association was largely confounded by differential ICI exposure: COPD-treated patients received ICIs more frequently (75.7% vs 44.4%), and when stratified by ICI status, COPD treatment showed benefit only in non-ICI patients and no meaningful difference in ICI-treated patients. The authors conclude that the survival association should be interpreted with consideration of ICI timing and exposure.
Multicenter, retrospective cohort study. 455 eligible patients with spirometry-confirmed COPD and advanced or recurrent NSCLC across four Japanese centres; 144 received regular inhaled COPD therapy, 311 did not. Excludes patients with sensitizing EGFR variants or ALK fusions.. Intervention: Regular inhaled COPD therapy (bronchodilators and/or inhaled corticosteroids) initiated before or at start of first-line NSCLC therapy. Compared with: No regular inhaled COPD therapy. n = 455. Four Japanese institutions.
Median OS longer in COPD-treated vs untreated group: 23.3 vs 16.7 months (HR 0.73, 95% CI 0.57–0.93; P = 0.0105) COPD-treated patients more likely to receive ICIs: 109/144 (75.7%) vs 138/311 (44.4%) In time-dependent Cox analysis, COPD treatment showed modest association with OS while ICI exposure showed nonsignificant trend
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians should recognize that any survival benefit associated with inhaled COPD therapy in advanced NSCLC is likely attributable to confounding by ICI exposure rather than direct therapeutic effect, since the benefit disappears when patients are stratified by ICI treatment. In the ICI era, ICI exposure—not COPD treatment status—is the dominant prognostic factor.
Retrospective cohort study showing that inhaled COPD therapy associates with longer overall survival in advanced NSCLC, but the effect is confounded by ICI use and disappears in ICI-treated patients, confirming that ICI is the dominant prognostic factor.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should recognize that any survival benefit associated with inhaled COPD therapy in advanced NSCLC is likely attributable to confounding by ICI exposure rather than direct therapeutic effect, since the benefit disappears when patients are stratified by ICI treatment. In the ICI era, ICI exposure—not COPD treatment status—is the dominant prognostic factor.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Immune checkpoint inhibitors (ICIs) have markedly improved survival in advanced non–small cell lung cancer (NSCLC), potentially modifying the prognostic impact of comorbid chronic obstructive pulmonary disease (COPD). We conducted a multicenter retrospective cohort study across four Japanese institutions including patients with spirometry-confirmed COPD and advanced or recurrent NSCLC, including stage IV disease, postoperative recurrence, recurrence after definitive concurrent chemoradiotherapy, or other advanced/recurrent status documented in the clinical records, treated between January 2007 and December 2020, excluding those with sensitizing EGFR variants or ALK fusions. COPD was diagnosed based on smoking history and airflow limitation, defined as a forced expiratory volume in 1 s (FEV1) to forced vital capacity (FVC) ratio of less than 70%, in accordance with the Japanese Respiratory Society guidelines and the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria. COPD treatment was defined as regular use of inhaled bronchodilators and/or inhaled corticosteroids initiated before or at the start of first-line therapy. Overall survival (OS) was measured from treatment initiation to death from any cause. Among 455 eligible patients with spirometry-confirmed COPD, 144 received regular inhaled COPD therapy and 311 did not. Median OS was longer in the COPD-treated group than in the untreated group (23.3 vs. 16.7 months; hazard ratio [HR] 0.73, 95% confidence interval [CI] 0.57–0.93; P = 0.0105). However, patients receiving COPD treatment were more likely to receive ICIs during the disease course than untreated patients (109/144, 75.7% vs. 138/311, 44.4%), and ICI therapy remained a strong independent predictor of OS in conventional multivariable analysis. In an additional time-dependent Cox analysis accounting for the timing of ICI initiation, COPD treatment showed a modest association with longer OS, whereas ICI exposure showed a nonsignificant trend toward improved OS. When patients were stratified by ICI exposure, COPD-treated patients had longer OS than untreated patients in the non-ICI subgroup, whereas OS did not differ meaningfully by COPD treatment status among patients who received ICIs. These findings indicate that the survival association between COPD treatment and OS should be interpreted with careful consideration of the timing and line of ICI exposure in the ICI era.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.